SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

Equity Bottom-Up

Scotts Miracle-Gro Co Cl A / Equity Bottom-Up

<figure>
 <img src='https://api2.sgx.com/sites/default/files/2020-05/SMG-CEO.jpg' alt='SMG-CEO' />
 </figure>
 <div class='content-caption'>SMG-CEO</div>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body>
For medical entrepreneur Dr Beng Teck Liang, taking the road less travelled nearly two decades ago has made a difference - and a serendipitous one at that. 
The scion of an urologist, Beng began his career as a Medical Officer with Singapore's Ministry of Health in 1996, after graduating from the UK's University of Manchester Medical School. 
"Although I was trained as a doctor, I wanted something more, so I decided to take a different path from my peers, and move from medicine to business," said the Chief Executive Officer of SGX-listed healthcare services provider Singapore Medical Group Ltd (SMG). 
So he retooled himself with a Master's in Business Administration from the University of Chicago's Booth School of Business and a General Management Programme from Harvard Business School. 
After spending the next decade managing multi-billion dollar businesses in information technology and healthcare across Asia Pacific for multinational corporations Hewlett-Packard and General Electric, Beng was ready once again to steer in a new direction. 
"I wanted to build something for myself. And when my partners and I saw the opportunity with SMG at that time, we decided to go for it," he recalled. "We launched a takeover and general offer for the company in 2013, and the rest is, undoubtedly, a beautiful history." 
However, the milestones that SMG achieved in the succeeding seven years did not come easy - hard decisions and sleepless nights were inevitable. 
"SMG had seen better days - its reputation was marred by controversy, business was shrinking, and we were months away from going broke. The stakes were really high at the time," Beng recalled. 
"We had to reorganise teams, cut costs, retrench or fire staff, before we could grow again. During the first year, I was constantly asking myself, What did I get myself into? Am I really going to make this work?" 
Determination and discipline, as well as biting not one, but several bullets, eventually yielded results. "We managed to turn around, slowly but surely, and looking back now, there's a tremendous sense of satisfaction," he added. 
And the proof, as they say, is in the pudding: For the year ended 31 December 2019, SMG reported a 11.3% year-over-year jump in revenue to a record S$94.7 million, driven by growth across all business segments. 
Operating cash flows rose to S$25.7 million for the year from S$16.8 million in FY2018. 
Today, SMG has a market capitalisation of more than S$120 million, up six-fold from its value of about S$20 million before the takeover. 
Incorporated in 2005 and listed on Singapore Exchange since 2009, SMG is a private specialist healthcare provider, with a comprehensive range of multidisciplinary specialties and an extensive network of Specialist and Associate doctors in clinics across Singapore. 
SMG's practices can be found in both central and suburban locations, including Paragon Medical Centre, Mount Elizabeth Medical Centre, Gleneagles Medical Centre, Mount Alvernia Medical Centre, as well as Bishan, Bedok, Toa Payoh and Punggol. Its specialties include Aesthetics, Cardiology, Dentistry, Medical Oncology, Obstetrics &amp; Gynaecology, Paediatrics, as well as Plastic and Reconstruction Surgery. Unswerving Focus 
Right from the start, Beng's vision for SMG was crystal-clear: Export the Singapore brand of healthcare - which is well-loved and well-respected in the region - beyond domestic shores. 
"Apart from the biggest players in this space, like Parkway Pantai and Raffles Medical Group, there are no small and medium companies who have a significant pan-Asian presence." 
SMG aims to change that. Today, it has an expanding footprint in Indonesia, a network of clinics in Vietnam, and a robust in-vitro fertilisation (IVF) business in Australia. "We were ahead of our peers in terms of taking that leap and targeting the markets, which are traditional sources of medical tourists in the region," Beng said. 
"Singapore's share of the region's medical tourism pie has been declining - we knew it would end at some point - so our goal was to bring the best-quality healthcare over to these countries. And I think we have made a lot of progress in achieving that." 
Apart from its regional footprint, the Group has also differentiated itself from competitors through its diversification strategy. "Our specialties cut across five verticals - cancer, aesthetics, paediatrics, diagnostics, as well as obstetrics and gynaecology - and we're a significant player in each vertical." 
SMG has also established a wide network of clinics across the city-state - of its 36 clinics, more than two-thirds are in the heartlands. It is incubating other businesses, while some potential verticals, like dental and ophthamology, have yet to grow to a significant size, Beng added. 
In partnership with South Korean healthcare group CHA Health Systems, SMG will actively pursue projects in Vietnam, Singapore, Oceania and other key Pacific Rim markets to address burgeoning demand for fertility services, as the region's birth rates continue to decline. 
The Group will also leverage CHA's expertise in anti-ageing care, as well as Korea's dermatology and aesthetics know-how, to boost its lead in various specialties, including oncology. 
"The CHA-SMG partnership is expected to lay the foundation for Asia-Pacific's first dedicated platform for comprehensive wellness care, spanning the anti-ageing, beauty and preventive care spectrums," he noted. 
Last year, an international unit of CHA invested S$50 million in SMG, raising its stake to 24.04% and becoming the Group's controlling shareholder. Silver Lining 
These days, what keeps the 48-year-old awake in the wee hours is none other than the COVID-19 outbreak. "This virtual enemy has complicated our previously simple growth strategy, which revolved around how fast we could expand, which markets to venture into, and which partners we should bring on board," he said. 
Lockdowns across the region have prevented ASEAN patients from carrying out their normal clinic visits. "COVID-19 will definitely impact us - about 20% to 30% of our business comes from ASEAN." 
Thankfully, there is a silver lining. "We unveiled our telehealth business at the beginning of last year, and are starting to reap the benefits of that," he noted. Patients can seek specialist care via tele-consultation through SMG's HiDoc platform, which is easily accessed via a mobile app or website. 
"We see huge opportunities in this space as medical tourism grinds to a halt from the pandemic." 
Looking back, Beng attributes SMG's success to key decisions made seven years ago, one of them being a "Buy and Grow" strategy. "Acquisitions helped us scale up and provided a catalyst for growth. Our verticals doubled or tripled in size after we came across opportunities to acquire clinics, and acted quickly," he said. 
"But we've never rested on our laurels - we're always mindful that we still need to maintain organic growth within our networks by opening new clinics and adding specialists." 
Between 2015 and 2019, SMG added more than 20 specialists to its fold, reflecting an 85% increase to 48 from 26. The pool has been expanding every year, largely through acquisitions of medical practices and the hiring of specialists from the public healthcare sector. 
At the end of the day, ushering SMG into its next phase of growth - and on the global stage, no less - is what keeps this father of two boys, aged 12 and 15, going. 
What's exciting is the fact that the Group has the opportunity to change how healthcare is perceived and delivered, both in this region and beyond, said Beng. 
"We're one of the biggest movers and shakers in the healthcare space now, because of the track record we've established over the last seven years," he pointed out. 
"SMG is part of a global collaborative platform that's growing, not just in Southeast Asia and the South Pacific, but in North Asia, and also further afield in the US and elsewhere." Singapore Medical Group Ltd 
Incorporated in 2005 and listed on SGX since 2009, Singapore Medical Group (SMG) is a private specialist healthcare provider with a comprehensive range of multidisciplinary specialties, and an extensive network of Specialist and Associate doctors located in clinics across Singapore. 
SMG's practices can be found at Paragon Medical Centre, Mount Elizabeth Medical Centre, Novena Medical Center, OUE Downtown Gallery, Gleneagles Medical Centre, Farrer Park Medical Centre@Connexion, and Mount Alvernia Medical Centre. Suburban locations include Bishan, Bedok, Toa Payoh and Punggol. Its specialties include Aesthetics, Cardiology, Dentistry, Medical Oncology, Obstetrics &amp; Gynaecology, Paediatrics, as well as Plastic and Reconstruction Surgery. 
The company website is: <a href="http://edm.sgx.com/a/hBetL0iB86%24MfB91z9HAAPJbdH7/link8">www.smg.sg</a>.

Click <a href="http://edm.sgx.com/a/hBetL0iB86%24MfB91z9HAAPJbdH7/link9">here</a> for the company's StockFacts page. 
For the full year ended 31 December 2019 financial results, click <a href="http://edm.sgx.com/a/hBetL0iB86%24MfB91z9HAAPJbdH7/link10">here</a>.
</body></html>


      
    
    SMG-CEO


For medical entrepreneur Dr Beng Teck Liang, taking the road less travelled nearly two decades ago has made a difference - and a serendipitous one at that.  
The scion of an urologist, Beng began his career as a Medical Officer with Singapore's Ministry of Health in 1996, after graduating from the UK's University of Manchester Medical School.  
"Although I was trained as a doctor, I wanted something more, so I decided to take a different path from my peers, and move from medicine to business," said the Chief Executive Officer of SGX-listed healthcare services provider Singapore Medical Group Ltd (SMG).  
So he retooled himself with a Master's in Business Administration from the University of Chicago's Booth School of Business and a General Management Programme from Harvard Business School.  
After spending the next decade managing multi-billion dollar businesses in information technology and healthcare across Asia Pacific for multinational corporations Hewlett-Packard and General Electric, Beng was ready once again to steer in a new direction.  
"I wanted to build something for myself. And when my partners and I saw the opportunity with SMG at that time, we decided to go for it," he recalled. "We launched a takeover and general offer for the company in 2013, and the rest is, undoubtedly, a beautiful history."  
However, the milestones that SMG achieved in the succeeding seven years did not come easy - hard decisions and sleepless nights were inevitable.  
"SMG had seen better days - its reputation was marred by controversy, business was shrinking, and we were months away from going broke. The stakes were really high at the time," Beng recalled.  
"We had to reorganise teams, cut costs, retrench or fire staff, before we could grow again. During the first year, I was constantly asking myself, What did I get myself into? Am I really going to make this work?"  
Determination and discipline, as well as biting not one, but several bullets, eventually yielded results. "We managed to turn around, slowly but surely, and looking back now, there's a tremendous sense of satisfaction," he added.  
And the proof, as they say, is in the pudding: For the year ended 31 December 2019, SMG reported a 11.3% year-over-year jump in revenue to a record S$94.7 million, driven by growth across all business segments. 
Operating cash flows rose to S$25.7 million for the year from S$16.8 million in FY2018.  
Today, SMG has a market capitalisation of more than S$120 million, up six-fold from its value of about S$20 million before the takeover.  
Incorporated in 2005 and listed on Singapore Exchange since 2009, SMG is a private specialist healthcare provider, with a comprehensive range of multidisciplinary specialties and an extensive network of Specialist and Associate doctors in clinics across Singapore.  
SMG's practices can be found in both central and suburban locations, including Paragon Medical Centre, Mount Elizabeth Medical Centre, Gleneagles Medical Centre, Mount Alvernia Medical Centre, as well as Bishan, Bedok, Toa Payoh and Punggol. Its specialties include Aesthetics, Cardiology, Dentistry, Medical Oncology, Obstetrics &amp; Gynaecology, Paediatrics, as well as Plastic and Reconstruction Surgery.  Unswerving Focus  
Right from the start, Beng's vision for SMG was crystal-clear: Export the Singapore brand of healthcare - which is well-loved and well-respected in the region - beyond domestic shores.  
"Apart from the biggest players in this space, like Parkway Pantai and Raffles Medical Group, there are no small and medium companies who have a significant pan-Asian presence."  
SMG aims to change that. Today, it has an expanding footprint in Indonesia, a network of clinics in Vietnam, and a robust in-vitro fertilisation (IVF) business in Australia. "We were ahead of our peers in terms of taking that leap and targeting the markets, which are traditional sources of medical tourists in the region," Beng said.  
"Singapore's share of the region's medical tourism pie has been declining - we knew it would end at some point - so our goal was to bring the best-quality healthcare over to these countries. And I think we have made a lot of progress in achieving that."  
Apart from its regional footprint, the Group has also differentiated itself from competitors through its diversification strategy. "Our specialties cut across five verticals - cancer, aesthetics, paediatrics, diagnostics, as well as obstetrics and gynaecology - and we're a significant player in each vertical."  
SMG has also established a wide network of clinics across the city-state - of its 36 clinics, more than two-thirds are in the heartlands. It is incubating other businesses, while some potential verticals, like dental and ophthamology, have yet to grow to a significant size, Beng added.  
In partnership with South Korean healthcare group CHA Health Systems, SMG will actively pursue projects in Vietnam, Singapore, Oceania and other key Pacific Rim markets to address burgeoning demand for fertility services, as the region's birth rates continue to decline.  
The Group will also leverage CHA's expertise in anti-ageing care, as well as Korea's dermatology and aesthetics know-how, to boost its lead in various specialties, including oncology.  
"The CHA-SMG partnership is expected to lay the foundation for Asia-Pacific's first dedicated platform for comprehensive wellness care, spanning the anti-ageing, beauty and preventive care spectrums," he noted.  
Last year, an international unit of CHA invested S$50 million in SMG, raising its stake to 24.04% and becoming the Group's controlling shareholder.  Silver Lining  
These days, what keeps the 48-year-old awake in the wee hours is none other than the COVID-19 outbreak. "This virtual enemy has complicated our previously simple growth strategy, which revolved around how fast we could expand, which markets to venture into, and which partners we should bring on board," he said.  
Lockdowns across the region have prevented ASEAN patients from carrying out their normal clinic visits. "COVID-19 will definitely impact us - about 20% to 30% of our business comes from ASEAN."  
Thankfully, there is a silver lining. "We unveiled our telehealth business at the beginning of last year, and are starting to reap the benefits of that," he noted. Patients can seek specialist care via tele-consultation through SMG's HiDoc platform, which is easily accessed via a mobile app or website.  
"We see huge opportunities in this space as medical tourism grinds to a halt from the pandemic."  
Looking back, Beng attributes SMG's success to key decisions made seven years ago, one of them being a "Buy and Grow" strategy. "Acquisitions helped us scale up and provided a catalyst for growth. Our verticals doubled or tripled in size after we came across opportunities to acquire clinics, and acted quickly," he said.  
"But we've never rested on our laurels - we're always mindful that we still need to maintain organic growth within our networks by opening new clinics and adding specialists."  
Between 2015 and 2019, SMG added more than 20 specialists to its fold, reflecting an 85% increase to 48 from 26. The pool has been expanding every year, largely through acquisitions of medical practices and the hiring of specialists from the public healthcare sector.  
At the end of the day, ushering SMG into its next phase of growth - and on the global stage, no less - is what keeps this father of two boys, aged 12 and 15, going.  
What's exciting is the fact that the Group has the opportunity to change how healthcare is perceived and delivered, both in this region and beyond, said Beng.  
"We're one of the biggest movers and shakers in the healthcare space now, because of the track record we've established over the last seven years," he pointed out.  
"SMG is part of a global collaborative platform that's growing, not just in Southeast Asia and the South Pacific, but in North Asia, and also further afield in the US and elsewhere."  Singapore Medical Group Ltd  
Incorporated in 2005 and listed on SGX since 2009, Singapore Medical Group (SMG) is a private specialist healthcare provider with a comprehensive range of multidisciplinary specialties, and an extensive network of Specialist and Associate doctors located in clinics across Singapore.  
SMG's practices can be found at Paragon Medical Centre, Mount Elizabeth Medical Centre, Novena Medical Center, OUE Downtown Gallery, Gleneagles Medical Centre, Farrer Park Medical Centre@Connexion, and Mount Alvernia Medical Centre. Suburban locations include Bishan, Bedok, Toa Payoh and Punggol. Its specialties include Aesthetics, Cardiology, Dentistry, Medical Oncology, Obstetrics &amp; Gynaecology, Paediatrics, as well as Plastic and Reconstruction Surgery.  
The company website is: www.smg.sg.

Click here for the company's StockFacts page.  
For the full year ended 31 December 2019 financial results, click here.



Singapore Medical Group Eyes Global Stage

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods.  In fact, during today's action, the 2760 support level on the S&amp;P 500 briefly held but ultimately gave way. With the SPX holding below 2760 today, we are looking for downside targets of 2650 first, and then potentially 2470 if that fails to hold.

Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods.  In fact, during today's action, the 2760 support level on the S&amp;P 500 briefly held but ultimately gave way. With the SPX holding below 2760 today, we are looking for downside targets of 2650 first, and then potentially 2470 if that fails to hold.

U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely

Both Energy and Materials have hurriedly advanced within our relative strength rankings over the past several weeks--now ranking #2 and #4, respectively--confirming the widespread patterns visible in the charts of each Sector’s constituents: bottoms and bases.We have highlighted these evolving set-ups over the past year, identifying: improving internals in energy (Aug. 12), then labeling it as a bottom the following week; also, reiterating copper nearly twelve months ago from today, recommending fertilizers (Dec. 13), and reiterating metals &amp; mining stocks (Dec. 18).Given the improving relative strength trends coupled with constructive patterns, we are upgrading both sectors to overweight from market weight.

Both Energy and Materials have hurriedly advanced within our relative strength rankings over the past several weeks--now ranking #2 and #4, respectively--confirming the widespread patterns visible in the charts of each Sector’s constituents: bottoms and bases.We have highlighted these evolving set-ups over the past year, identifying: improving internals in energy (Aug. 12), then labeling it as a bottom the following week; also, reiterating copper nearly twelve months ago from today, recommending fertilizers (Dec. 13), and reiterating metals &amp; mining stocks (Dec. 18).Given the improving relative strength trends coupled with constructive patterns, we are upgrading both sectors to overweight from market weight.

Upgrading U.S. Energy & Materials Sectors to Overweight

CHINA - Healthcare, Steel, Autos, Education, Research From Beijing

Scott Laprise/ 乐天虎

CHINA - Healthcare, Steel, Autos, Education

Thematic (Sector/Industry)

The market is expecting US tariffs on Chinese steel exports wrongly believing Chinese are major steel   exporters to the US.Steel exports to US from China are low at about 2.9mt in November. If the US adds more steel tariffs, it will have little impact to the steel market or prices but it will possibly cause a retaliation by the Chinese.China only exports 26% of Global Steel Exports, far lower than the 50% of their total global steel production. Most of Chinese steel exports go to other Asian…

The market is expecting US tariffs on Chinese steel exports wrongly believing Chinese are major steel   exporters to the US.Steel exports to US from China are low at about 2.9mt in November. If the US adds more steel tariffs, it will have little impact to the steel market or prices but it will possibly cause a retaliation by the Chinese.China only exports 26% of Global Steel Exports, far lower than the 50% of their total global steel production. Most of Chinese steel exports go to other Asian…

Market Is Wrong on US Tariffs for Chinese Steel

Macro Strategist, Saxo Capital Markets

Kay Van-Petersen

Macro Strategist

Saxo Capital Markets

<ul><li>It's time to break out the analysis on gold and silver miners</li><li>Some goldminers are trading well below P/B, with potential price moves of +4x just to get back to median P/B levels</li><li>Fed week: watch for dovishness; US GDP watch for a miss. Both of these plus coming up to month end could add to near-term equity bullish sentiment</li><li>Central bank meetings include Japan, New Zealand, South Africa, Russia and Nigeria</li></ul>

It's time to break out the analysis on gold and silver minersSome goldminers are trading well below P/B, with potential price moves of +4x just to get back to median P/B levelsFed week: watch for dovishness; US GDP watch for a miss. Both of these plus coming up to month end could add to near-term equity bullish sentimentCentral bank meetings include Japan, New Zealand, South Africa, Russia and Nigeria

The Macro Take: Get the Picks Out for Gold and Silver Miners

United States

The Scotts Miracle-Gro Company markets branded consumer lawn and garden products, as well as a full range of products for professional horticulture. The Company manufactures and markets fertilizers, pest controls, plant foods, gardening soils, grass seed, and other products in North America and Europe. Scotts Miracle-Gro also provides lawn service in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scotts Miracle-Gro Co Cl A (SMG US)

Singapore Medical Group Eyes Global Stage

For medical entrepreneur Dr Beng Teck Liang, taking the road less travelled nearly two decades ago has made a difference - and...

Singapore Exchange Ltd (SGX)

U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely

Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...

Vermilion Research

Upgrading U.S. Energy & Materials Sectors to Overweight

Both Energy and Materials have hurriedly advanced within our relative strength rankings over the past several weeks--now ranking #2 and #4,...

Vermilion Research

Market Is Wrong on US Tariffs for Chinese Steel

The market is expecting US tariffs on Chinese steel exports wrongly believing Chinese are major steel exporters to the US.Steel exports to US...

Scott Laprise/ 乐天虎

The Macro Take: Get the Picks Out for Gold and Silver Miners

It's time to break out the analysis on gold and silver miners Some goldminers are trading well below P/B, with potential price moves of +4x just...

Kay Van-Petersen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)